Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Bliss GVS Pharma Ltd. Share Price
Day's Range
Day's Range
Low
₹448.45
High
₹462.80
Price Summary
| Previous Close | ₹450.10 |
|---|---|
| Day's Range | ₹448.45 - ₹462.80 |
| Open | ₹457.00 |
| 52 Week Range | ₹118.00 - ₹553.00 |
| Volume | 3,30,285 |
| Market Cap | ₹0.00 |
| Previous Close | ₹453.90 |
|---|---|
| Day's Range | ₹448.00 - ₹459.90 |
| Open | ₹455.00 |
| 52 Week Range | ₹118.35 - ₹552.90 |
| Volume | 8,564 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 1,486.61 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.33 |
| Price/Earning (TTM) | 37.93 |
| TTM EPS (₹) | 12.15 |
| P/E Ratio | 17.66 |
| Book Value(₹) | 4.15 |
| PAT Margin (%) | 13.91 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 17.40 |
| Trade Value ( ₹ in Lacs) | 38.87 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.33 |
| Price/Earning (TTM) | 37.93 |
| TTM EPS (₹) | 12.15 |
| P/E Ratio | 17.66 |
| Book Value(₹) | 4.15 |
| PAT Margin (%) | 13.91 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 17.40 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 1979.86 | 6672.05 |
| Expenses | N/A | N/A |
| PBT | 234.4 | 941.71 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 166.53 | 689.69 |
About Bliss GVS Pharma Ltd.
| Founded | 1984 |
|---|---|
| Managing Director | Narsimha Shibroor Kamath |
| NSE Symbol | BLISSGVS |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,73,508.76 | 1,977.20 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,96,880.79 | 7,437.65 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,90,832.46 | 4,895.00 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,27,148.77 | 8,939.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,13,894.07 | 1,444.65 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,10,523.42 | 1,101.65 | 835.50 - 835.50 |
| Lupin Ltd. | 1,10,189.04 | 2,398.45 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,08,476.19 | 1,104.85 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,05,357.34 | 2,628.00 | 1,909.70 - 1,909.70 |
| Lenskart Solutions Ltd. | 99,446.13 | 556.00 | 0.00 - 0.00 |
No Records Found
Latest News
Bliss GVS Pharma informs about closure of trading window
Bliss GVS Pharma has informed that pursuant to the Securities Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force) and in accordance with the Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons, the Trading window for dealing in securities/shares of the Company will remain closed for Insiders, Designated Persons and their immediate relatives of the Company with effect from Wednesday, July 01, 2026 till completion of 48 hours after the announcement of the Unaudited Financial Results of the Company for the quarter ended on June 30, 2026 generally made available to the public. The Board meeting for the declaration of Unaudited Financial Results for the quarter ended June 30, 2026, shall be intimated later. Accordingly, Insiders, Designated Persons, and their immediate relatives are advised not to trade (buy or sell or pledge, etc.) in the securities/shares of the Company during the aforesaid period of closure of the Trading Window.
Bliss GVS Pharma informs about open offer
Bliss GVS Pharma informs about disclosure
Zenotech Laboratories informs about outcome of board meeting
Further to the communication dated July 13, 2026, pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’) Zenotech Laboratories has informed that the Meeting of the Board of Directors of the Company was held today, July 28, 2026, which commenced at 11:30 AM and concluded at 2:30 PM, IST. The Board has, 1. Approved Unaudited Standalone Financial Results - The Unaudited Standalone Financial Results for the quarter ended June 30, 2026, as approved pursuant to Regulation 33 of the Listing Regulations, along with the Limited Review Report of the Statutory Auditors, are annexed herewith as Annexure A. 2. Approved convening 37th Annual General Meeting - The 37th Annual General Meeting (‘AGM’) of the Company will be held on Friday, September 25, 2026, at 10:30 AM IST through Videoconferencing. The Notice of the AGM and the Annual Report will be released in due course. Shareholders are requested to get their information updated with the depositories (for shares held in demat) or with the Company’s RTA (for shares held in physical form), so that Notice of the AGM and the Annual Report can be received by email.
The above information is a part of company’s filings submitted to BSE.
Indoco Remedies informs about change in management
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Bliss GVS Pharma Ltd. is ₹450.10 as of 2026-07-28.
The market capitalisation of Bliss GVS Pharma Ltd. is ₹4,897.85 as of 2026-07-27.
The 1-year return of Bliss GVS Pharma Ltd. is 296.49% as of 2026-07-28.
The P/E ratio of Bliss GVS Pharma Ltd. is 17.66 as of 2026-07-28.
The 52-week high and low of Bliss GVS Pharma Ltd. are ₹553.00 and ₹118.00, respectively, as of 2026-07-28.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
